Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Belgium-based biopharmaceutical company UCB has announced that the FDA has approved Keppra XR for use as an add-on to other antiepileptic treatments for people with partial-onset seizures who are 16 years of age and older.
Subscribe to our email newsletter
Keppra XR is expected to be available in US pharmacies at the end of September 2008.
The goal of therapy with antiepileptic drugs is freedom from seizures and minimal side effects, the company said.
Troy Cox, senior vice president of UCB, said: “This is one of many milestones at UCB to develop new treatment options for people with epilepsy. Keppra XR provides a way to simplify treatment and offers another chance to achieve seizure control, which is an important goal for patients living with epilepsy.”